BioLife Solutions, Inc. (NASDAQ:BLFS) Shares Acquired by 1620 Investment Advisors Inc.

1620 Investment Advisors Inc. lifted its stake in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 41.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,295 shares of the medical equipment provider’s stock after purchasing an additional 675 shares during the period. 1620 Investment Advisors Inc.’s holdings in BioLife Solutions were worth $60,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. State Street Corp boosted its holdings in shares of BioLife Solutions by 7.3% during the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock worth $35,364,000 after purchasing an additional 95,788 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of BioLife Solutions by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock worth $21,107,000 after purchasing an additional 18,473 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of BioLife Solutions by 40.8% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 19,463 shares of the medical equipment provider’s stock worth $487,000 after purchasing an additional 5,638 shares during the last quarter. Barclays PLC raised its position in shares of BioLife Solutions by 20.1% during the 3rd quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider’s stock valued at $1,613,000 after buying an additional 10,803 shares during the period. Finally, D.A. Davidson & CO. purchased a new stake in shares of BioLife Solutions during the 3rd quarter valued at approximately $1,018,000. 93.24% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at BioLife Solutions

In related news, insider Sarah Aebersold sold 5,632 shares of the business’s stock in a transaction on Friday, March 14th. The shares were sold at an average price of $24.96, for a total transaction of $140,574.72. Following the completion of the transaction, the insider now owns 45,860 shares in the company, valued at approximately $1,144,665.60. The trade was a 10.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Troy Wichterman sold 4,151 shares of the business’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total transaction of $103,775.00. Following the transaction, the chief financial officer now owns 116,809 shares of the company’s stock, valued at approximately $2,920,225. The trade was a 3.43 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 21,117 shares of company stock valued at $534,442. 2.20% of the stock is currently owned by company insiders.

BioLife Solutions Stock Down 0.3 %

BioLife Solutions stock opened at $24.99 on Friday. BioLife Solutions, Inc. has a twelve month low of $14.84 and a twelve month high of $29.55. The stock’s fifty day simple moving average is $26.40 and its 200-day simple moving average is $25.48. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $1.17 billion, a P/E ratio of -23.58 and a beta of 2.04.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The business had revenue of $22.71 million for the quarter, compared to analyst estimates of $21.73 million. During the same quarter in the prior year, the company earned ($0.21) earnings per share. As a group, equities analysts expect that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on BLFS. Benchmark reaffirmed a “buy” rating and set a $30.00 price target on shares of BioLife Solutions in a research report on Thursday, December 19th. Northland Securities lifted their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research report on Wednesday, January 8th. StockNews.com raised BioLife Solutions from a “sell” rating to a “hold” rating in a research report on Wednesday. KeyCorp boosted their target price on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. Finally, HC Wainwright boosted their target price on BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.86.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.